Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-0610 + Dasatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-0610||CPI0610||BET Inhibitor (Pan) 31||CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195, PMID: 31729905).|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 27 BTK inhibitor 25 CSF1R Inhibitor 26 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 30 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||CPI-0610 + Dasatinib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination treatment of Sprycel (dasatinb) and CPI-0610 resulted in a synergistic effect, demonstrating greater inhibition of colony formation in ovarian cancer cells in culture compared to either therapy alone (PMID: 32927276).||32927276|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|